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Abstract
Background: The role of B cells in allergic asthma remains undefined. One mechanism by which B cells clearly contribute to
allergic disease is via the production of specific immunoglobulin, and especially IgE. Cognate interactions with specific T
cells result in T cell help for B cells, resulting in differentiation and immunoglobulin secretion. Proximal to (and required for)
T cell-dependent immunoglobulin production, however, is antigen presentation by B cells. While interaction with T cells
clearly has implications for B cell function and differentiation, this study investigated the role that B cells have in shaping the
T cell response during chronic allergic lung disease.
Methodology/Principal Findings: In these studies, we used a clinically relevant mouse model of chronic allergic lung disease
to study the role of B cells and B cell antigen presentation in this disease. In these studies we present several novel findings: 1)
Lung B cells from chronically allergen challenged mice up-regulated MHC II and costimulatory molecules CD40, CD80 and
CD86. 2) Using in vitro studies, B cells from the lungs of allergen challenged mice could present antigen to T cells, as assessed
by T cell proliferation and the preferential production of Th2 cytokines. 3) Following chronic allergen challenge, the levels of
Th2 cytokines IL-4 and IL-5 in the lungs and airways were significantly attenuated in B cell 2/2 mice, relative to controls. 4) B
cell driven Th2 responses and mucus hyper secretion in the lungs were dependent upon MHC II expression by B cells.
Conclusions/Significance: Collectively, these results provide evidence for antigen presentation as a novel mechanism by
which B cells contribute to chronic allergic disease. These findings give new insight into the mechanisms by which B cells
promote asthma and other chronic diseases.
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Introduction
In recent decades, the prevalence of asthma in the US and other
industrialized countries has increased dramatically [1,2,3]. Al-
though some recent data suggest that the incidence of asthma may
have reached a plateau [4,5], it remains a major public health
concern. Chronic allergic lung disease (allergic asthma) accounts
for a majority of asthma. The disease is variable, but is
characterized by pulmonary inflammation, eosinophilia, and
mucus hyper secretion, leading to impaired lung function.
Therapeutic options for allergic asthma include corticosteroids,
antihistamines, and eicosanoid inhibitors. Recent developments in
molecular therapies, including monoclonal anti-IgE, provide
substantial benefit potential, but have limitations based on the
cost of therapy [6]. The responsible use of these, as well as the
development of other novel therapies, depends upon a proper
understanding of the mechanisms which contribute to the
development of allergic disease.
Many studies have demonstrated that Th2 cytokines play an
important role in the development of allergic lung disease and the
downstream events, including inflammation, eosinophilia, mast
cell accumulation/activation, and airway remodeling
[7,8,9,10,11,12,13,14]. However, less is known about the mech-
anisms which affect the development and maintenance of Th2
cells. The initiation of pulmonary immune responses begins with
recognition of antigen by pulmonary antigen presenting cells
(APC), which traffic to lung associated lymph nodes. APCs in the
lymph nodes prime initial T cell responses, which proliferate and
traffic to the lungs. The mechanisms responsible for the
perpetuation of allergic disease are poorly understood, although
these likely represent a balance between pro-inflammatory signals
such as infection or allergen exposure, countered by anergic and
tolerogenic mechanisms [15,16].
The role of B cells in the development and maintenance of
allergic disease remains unresolved. Previous studies concerning B
cells in allergic disease have concluded that B cells play no role in
the development of allergic disease as characterized by inflamma-
tion, eosinophilia, and AHR [17,18]. Other studies have suggested
that the contribution of B cells is primarily via IgE [19,20]. Still
other studies which support a role for B cells in allergic lung
disease did not directly address the mechanism by which B cells
contribute to allergic disease [21,22]. Significant numbers of B
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In these studies, we sought to determine the role of B cells in the
pathogenesis of chronic allergic disease, with specific attention to
the role of B cells as antigen-presenting cells.
Results
Accumulation of B cells at the sites of inflammation
during allergen-induced chronic lung disease
Our first objective in these studies was to determine whether B
cells are a significant component of the inflammation associated
with chronic allergic disease. To this end, mice were chronically
challenged with cockroach antigen as detailed in Fig. 1A. At
various time points following initial challenge, the numbers of
CD19
+ B cells, CD4
+ T cells, and CD8
+ T cells in the lungs were
determined by flow cytometric analysis of enzymatic digests. In the
lungs, nearly 1.6610
6 B cells were present in naı ¨ve lungs (Fig. 1B).
The number of pulmonary B cells increased significantly following
intranasal challenge, but following intratracheal challenge of a
larger bolus of allergen, the number of pulmonary B cells
increased dramatically, to over 3610
6 cells (3.1660.35). The
number of B cells in the lungs of chronically allergic mice was
similar to the number of CD4
+ T cells in these mice
(3.2460.24610
6). In comparison, very few CD8
+ T cells
accumulated in response to allergen challenge. To determine
whether cockroach antigen - specific B cells were present in this
inflammatory response, the frequency of CRA-specific B cells in
various organs was assessed via a combination of ELISPOT
analysis and flow cytometry. In response to allergen challenge, the
frequency of CRA-specific B cells increased in the bone marrow,
lung-draining lymph nodes, and in the lungs (Fig. 1C). Thus, B
cells (both specific, and non-specific) are a major component of the
pulmonary inflammation associated with chronic allergen-induced
allergic disease.
B cell costimulatory molecule expression in the lungs of
chronic allergen challenged mice
One mechanism by which B cells could potentially influence
allergic disease is via antigen presentation. We first determined
whether B cells in the lungs of allergen challenged mice express
MHC II and costimulatory molecules required for stimulating
infiltrating T cells. B cells were isolated from the lungs of allergen
challenged mice and assayed via flow cytometry for the expression
of MHC II, CD40, CD80, and CD86, as described in the
Methods. B cells from the lungs of allergen challenged mice
expressed high levels of MHC II, CD40, CD80, and CD86
(Fig. 2A). We next wanted to determine whether the expression of
MHC II and costimulatory molecules were increased during the
course of allergen challenge. To address this question, pulmonary
B cell expression of MHC II and costimulatory molecules were
assessed at various time points post-challenge. Following sensiti-
zation (day 13), the expression of CD40 by pulmonary B cells was
increased slightly relative to B cells from naive lungs (Table 1).
However, no increases in MHC II, CD80, nor CD86 were present
at this time point. Similarly, at day 15 (1 day after the first
intranasal challenge), the expression of MHC II and costimulatory
molecules were similar to naive lung B cells. However, following
chronic allergen challenge (d37), the expression of MHC II,
CD80, and CD86 were dramatically up-regulated relative to B cell
from the lungs of naı ¨ve mice (Table 1). Although B cells from the
spleen also exhibited an increase in MHC II at day 37, the
increased expression of costimulatory molecules was present only
in the lungs (Table 1). These results demonstrate that B cells in the
lungs of allergen-challenged mice express costimulatory molecules,
as well as high levels of MHC II, consistent with a role as antigen
presenting cells.
Pulmonary B cells induce allergen-dependent
preferential Th2 cytokine production
Th2 cytokines play an important role in the development of
chronic allergic lung disease. Our next objective was to determine
whether B cells from the lungs of allergen challenged mice could
present antigen to lung T cells, and determine the nature of the
resulting cytokine response. In the lungs, a number of potential
antigen presenting cells are present, including macrophages,
dendritic cells, as well as B cells. To determine whether B cells
could function directly as APCs, we purified B cells from the lungs
of allergen challenged mice by FACS (.99% CD19
+, ,0.1%
CD11c
+) and determined their ability to induce antigen-dependent
Th2 cytokine production by CD4
+ T cells in vitro. As expected,
CD4
+ T cells alone (.99.5% pure) produced no detectable IL-4,
IL-5, IL-13, IL-17 or IFNc (Fig. 3). Upon addition of antigen, no
increase in cytokine production was observed, confirming the
purity of the CD4
+ T cell isolation (Fig. 3). T cells co-cultured with
B cells and antigen produced high levels of the Th2 cytokines IL-
13, IL-4, and IL-5, but very little of the Th1 cytokine IFNc or the
Th17 cytokine IL-17 (Fig. 3). These data demonstrate that B cells
from allergic lungs can take up, process, and present antigen to
lung CD4
+ T cells, resulting in Th2 cytokines production.
Pulmonary B cells induce antigen-dependent T cell
proliferation
To determine whether B cells from the lungs of chronically
allergen challenged mice could promote T cell proliferation, CD4
+
T cells were purified from allergen challenged mice by magnetic
separation (MACS) and stained with CFSE as described in the
Methods. CFSE- stained T cells were co-cultured with lung B cells
with or without cockroach antigen, and the resulting proliferation
was assessed via flow cytometry. Very little proliferation was
observed in cultures with T cells alone (Fig. 4B), with less than 5%
of the cells dividing (Fig. 4B). When cockroach antigen was added
to T cells, a slight decrease in CFSE intensity was apparent
(Fig. 4A), reflecting some CD4
+ T cell proliferation (,20%,
Fig. 4B). This may be due to low-level contamination of the CD4
+
T cell preparation by APCs (purity .95% CD4
+ T cells).
Alternatively, these may represent CD4
+ T cells dividing as a
result of signals received in vivo. No increase in proliferation was
observed upon addition of B cells without antigen (Fig 4B). In
cultures with T cells, antigen, and B cells, CD4
+ T cells exhibited a
more robust proliferative response (Fig. 4A) with .50% of the cells
dividing (Fig. 4B) and a proliferation index of ,0.7 (Fig. 4B).
These data demonstrate that purified lung B cells promote
antigen-dependent proliferation of CD4
+ T cells in vitro.
Role of B cells in allergen-induced pathophysiology
Previous studies have suggested that B cell deficient mice
develop inflammation and eosinophilia equivalent to wild-type
mice in ovalbumin models of allergic lung disease [17,18]. Our
data suggest that B cells accumulate in the lungs dramatically over
time during a more chronic allergen exposure (Fig. 1B). To
determine the role of B cells in chronic allergic lung disease, we
subjected B cell deficient (mMT) and wild-type mice to the protocol
described in Fig. 1A. One of the hallmarks of allergic disease is
airway hyperreactivity (AHR). In response to methacholine
challenge, control B6 mice exhibited robust airway hyperreactivity
(Fig. 5A). B cell 2/2 mice had significantly attenuated AHR,
compared to controls (Fig. 5A). These data demonstrate that B
B Cells Promote Th2 Responses
PLoS ONE | www.plosone.org 2 September 2008 | Volume 3 | Issue 9 | e3129i.p./s.c. i.n. i.n. i.n. i.n. i.t. i.t.
14 0 18 22 26 34 36 37
Cockroach Antigen (CRA)
# cells/
lung
(x 106)
A
B
Days Post-Priming
*
0
1
2
3
4
01 0 2 0 3 0 4 0
B
CD4
CD8
*
* *
*
*
0
50
100
150
200
250
300
350
Naive CRA
Lungs Lymph
Nodes
Spleen Bone
Marrow
Naive CRA Naive CRA Naive CRA
CRA-
Specific
B cells
(per 106)
*
*
*
C
Figure 1. Accumulation of B cells in the lungs during chronic allergic lung disease. (A) Chronic model of cockroach antigen-induced
allergic lung disease. Mice were immunized intraperitoneally (i.p.) and subcutaneously (s.c.), followed by 4 intranasal (i.n.) challenges, and two
intratracheal (i.t.) inoculations. (B) Kinetics of B and T cell accumulation in the lungs of allergen challenged mice. The numbers of CD4
+, CD8
+, and
CD19
+ cells were determined by flow cytometric analysis of enzymatically digested lungs. Each time point represents the mean of 5 mice per group
6SEM *=p,0.05 vs. naı ¨ve lung . Similar results were observed in two independent experiments. (C) Cockroach antigen-specific B cells in the lungs,
lymph nodes, spleen, and bone-marrow of naı ¨ve and allergen challenged (day 37) mice. The frequency of specific B cells was determined by a
combination of ELISPOT and flow cytometry, as described in Materials and Methods. Bars represent the mean of 5 mice per group 6SEM *=p,0.05
vs. naı ¨ve. Similar results were observed in two independent experiments.
doi:10.1371/journal.pone.0003129.g001
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lung disease. Another hallmark of allergic lung disease is the hyper
secretion of mucus in the airways. To determine whether B cells
contribute to inflammation and mucus hyper secretion, lung
sections from B cell 2/2 and control mice were stained with
periodic acid schiff’s (PAS) or Hemotoxyolin and Eosin (H&E).
Inflammation and PAS staining were equivalent between the two
groups of mice (Fig. 5B, 5C). Thus, B cells contribute to airway
hyperreactivity in chronic allergen-challenged mice, but the
decreased AHR observed in B cell 2/2 mice was not associated
with gross changes in inflammation or mucus hyper secretion.
Role of B cells in influencing inflammatory cell
recruitment to the lungs of allergen challenged mice
Chronic allergic lung disease is associated with sustained
inflammatory cell infiltration of the lungs. Our next objective
was to determine whether B cells play a role in the magnitude or
character of the inflammatory cell influx during chronic allergic
disease. To this end, lungs of allergen challenged control and B cell
2/2 mice were enzymatically digested, and the numbers of
CD45
+, CD4
+, CD8
+, and CD19
+ cells were quantified by flow
cytometry, as described in the Methods. The number of CD45
+
(or common leukocyte antigen) expressing cells in the lungs gives a
quantitative measure of the magnitude of inflammation. The
numbers of CD45
+ leukocytes, as well as CD4
+ and CD8
+ T cells
were similar between the two groups (Fig. 6A). Thus, B cells did
not significantly affect the overall magnitude of the inflammatory
response during chronic allergic lung disease. Chronic allergic
lung disease is typically accompanied by an influx of eosinophils to
the lungs. To determine whether B cells played a role in eosinophil
accumulation in the lungs, the number of eosinophils in the lungs
was determined via differential counts of cytospins of enzymati-
cally digested lungs. The absolute number of eosinophils was
determined by multiplying the frequency by the total cell count for
that lung (obtained using a hemocytometer), as described in the
Methods. No differences in eosinophilic frequency (Fig. 6B) or
absolute number (Fig. 6C) were observed in the lungs of control
versus B cell 2/2 mice. Taken together, these data demonstrate
that B cells do not alter the pulmonary inflammatory cell influx
during chronic allergic lung disease.
Levels of Th1, Th2, and Th17-associated cytokines in the
lungs of chronic allergen challenged mice
The development of allergic lung disease is dependent on the
production of Th2-associated cytokines IL-4, IL-5, and IL-13. The
role of IL-17 in allergic disease is as yet unclear, but IL-17 may
also play a role in promoting mucus hyper secretion [23,24,25,26].
We next determined how B cells contribute to the production of
Th1, Th2, and Th17 cytokines in the lungs of chronic allergic
mice. Control and B cell 2/2 were chronically challenged with
CRA and the levels of Th2 cytokines in the lungs were determined
by analysis of whole lung homogenates and bronchoalveolar
lavage by Bioplex multiplex assay. Following chronic allergen
challenge, IL-4, IL-5, IL-13, and (to a lesser degree) IFNc and IL-
17 were up-regulated in the lungs and airways of control allergen
challenged mice (Fig. 7A, 7B). In B cell 2/2 mice, the production
of the Th2 cytokines IL-4 and IL-5 was significantly attenuated, in
both lungs and BAL (Fig. 7A, 7B). While not absolute, the
reduction in Th2 cytokines in B cell 2/2 mice was .60% in BAL
MHC II
CD40
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% Max
% Max
% Max
% Max
Figure 2. Expression of MHC II and costimulatory molecules by
B cells from the lungs of chronic allergen challenged mice (day
37). Lung leukocytes were recovered from the lungs via enzymatic
digests and the expression of MHC II, CD40, CD80, and CD86 on CD19
+
cells were determined by flow cytometry. Representative histograms
(from a group of n=5) are shown. Shaded histograms represent isotype
controls, with overlays representing MHC II, CD40, etc.
doi:10.1371/journal.pone.0003129.g002
Table 1. B cell costimulatory molecule expression in the
lungs and spleens of naive and cockroach allergen challenged
mice at various time points post-challenge.
Naive d13 d15 d37
Lungs
CD40 13.3360.36 15.3060.12 * 14.2860.06 15.5160.45 **
CD80 9.6360.96 8.9060.82 8.9060.99 15.0362.13 *
CD86 21.8360.86 24.3661.31 20.1661.74 55.9365.07 **
MHC II 585.93635.93 639.276104.29 609.2265.98 1302.33655.07 **
Spleen
CD40 13.1660.56 14.5760.25 13.8660.15 12.5360.40
CD80 26.1961.2 26.7461.1 28.1862.14 25.2062.05
CD86 9.1061.1 9.8660.89 8.4660.97 11.9060.91
MHC II 608.10638.6 583.07628.13 510.51612.56 761.706101.2 *
Mice were euthanized at various time points during chronic allergen
sensitization and challenge. Lungs and spleens were removed, enzymatically
digested, and the expression of the various markers determined by flow
cytometry. The median fluoresence intensity (MedFI) of CD40, etc. by CD19
+
cells from naive, ip/sc sensitized (d13), single intranasal challenge (d15), and
chronically challenged (d37) mice are shown. Bars represent the mean of 5 mice
per group 6SEM.
*=p,0.05 vs. naı ¨ve.
**=p,0.01 vs. naı ¨ve. Similar results were
observed in two independent experiments.
doi:10.1371/journal.pone.0003129.t001
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Figure 3. Th2 cytokine production in pulmonary B cell/T cell co-cultures. Lung lymphocytes were isolated from chronic allergen challenged
mice (day 37) by enzymatic digest and enriched by density gradient centrifugation. Lung CD4
+ T cells and CD19
+ B cells were isolated via
fluorescence activated cell sorting (FACS), and co-cultured at a ratio of 4:1 (T:B), with and without cockroach antigen. CD4
+T and CD19
+B cells were
.99% pure, and contained ,0.05% CD11c
+ cells, as determined by post-sort analysis. (A) Cytokine levels in culture supernatants were determined via
Bioplex-based multiplex assay after 48 hours in culture. Bars represent the mean of triplicate wells 6SEM. *=p,0.05 vs. T cell/B cell co-cultures
without cockroach antigen. Similar results were observed in three independent experiments. (B) In a parallel experiment, cytokine mRNA levels were
determined after 24 hour in culture via quantitative PCR. Bars represent the mean of triplicate wells 6SEM. *=p,0.05 vs. cells without antigen.
Similar results were observed in two independent experiments.
doi:10.1371/journal.pone.0003129.g003
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was increased in B cell2/2 mice, relative to controls (Fig. 7A, B).
CD4
+ T cells in the lungs of B cell 2/2 mice had significantly
lower frequencies of IL-4 production, as assessed by intracellular
cytokine staining (Fig. 7C). Interestingly, no IL-17 production by
CD4
+ T cells was detected via intracellular cytokine staining (data
not shown), suggesting that IL-17 in this system is primarily non-T
cell-derived. Together, these results demonstrate that B cells play a
role in promoting the production of Th2 cytokines IL-4 and IL-5,
but limiting IL-17 during chronic allergic lung disease.
Role of B cell MHC II expression on the development of
Th2 cytokine production and pathophysiology during
chronic allergic lung disease
To determine whether decreased Th2 cytokines and attenuated
pathophysiology observed in B cell 2/2 mice were dependent
upon antigen presentation by B cells, we used mixed bone marrow
chimeras, as previously described [27]. B cell deficient mMT mice
were reconstituted with a mixture of 75% mMT/25% WT bone
marrow or 75% mMT/25% MHC II2/2 bone marrow. Mice
receiving MHC II 2/2 bone marrow thus receive only MHC
II2/2 B cells, whereas other APCs are largely normal. Mice were
rested for eight weeks, then chronically challenged with allergen.
The levels of Th2 cytokines in the lungs were determined by
analysis of whole lung homogenates. Similar to the results obtained
in Fig. 7, B cell expression of MHC II resulted in enhanced IL4
and IL-5, but not IL-13 or IFNc (Fig. 8A). B cell expression of
MHC II also increased the production of IL-17, relative to mice
receiving MHC II2/2 B cells. Additionally, the expression of
mucus associated genes Muc5ac and Gob5 were significantly
increased in wild-type B cell reconstituted mice, relative to
MHC II 2/2 controls (Fig. 8B). While not statistically significant,
there was a trend towards decreased inflammatory cells in mMT/
MHC II2/2 chimeric mice (Table 2). These data demonstrate
that B cell driven Th2 cytokine production and pathophysiology
during chronic allergic lung disease is at least partially MHC-II
dependent. These data strongly suggest that B cell antigen
presentation contributes to the pathogenesis of chronic allergic
lung disease.
Discussion
B cell infiltration of diseased tissues occurs in a variety of
chronic diseases, including allergic lung disease, though their
contribution to disease remains enigmatic. Although some other
studies have demonstrated that B cells can contribute to airway
hyperresponsiveness during allergic lung disease, these findings
were ascribed to the production of antibodies (and IgE, in
particular). Our studies are the first to provide evidence that
antigen presentation by B cells contributes to the pathogenesis of
allergic disease. In support of this mechanism, our studies
demonstrate that: 1) Allergic disease results in the accumulation
of large numbers of B cells to the lung parenchyma (a high
frequency of which are antigen-specific). 2) Pulmonary B cells
present antigen to T cells in vitro, as assessed by T cell proliferation
and the production of Th2 cytokines. 3) Following chronic allergen
challenge, B cell 2/2 mice (mMT) had attenuated airway AHR,
and decreased Th2 cytokines IL-4 and IL-5. 4) Th2 cytokine
production and allergic disease were attenuated in mice selectively
deficient in MHC II on B cells. Thus, B cell antigen presentation
plays an important role at promoting Th2 responses and
pathophysiology during chronic allergic lung disease.
Although present in naı ¨ve lungs, our studies found that B cells
increase dramatically in the lungs over the course of a chronic
response. B cells accumulate during a number of chronic
inflammatory diseases, including chronic obstructive pulmonary
disease (COPD), rheumatoid arthritis (RA), and multiple sclerosis
[28]. Severe COPD is often accompanied by the formation of B
cell-containing lymphoid follicles surrounding airways and in the
lung parenchyma, as well as B cell infiltration of airways
[29,30,31]. Similarly, B cell follicles develop in rheumatoid
synovial lesions of some patients. [32]. Normally present at very
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Figure 4. In vitro proliferative responses of T cells co-cultured
with pulmonary B cells. Lymphocytes were isolated from chronic
allergen challenged mice via enzymatic digest and density gradient
centrifugation. CD4
+ T cells and pulmonary CD19
+ B cells were isolated
via magnetic separation (MACS). Purity of isolated cell populations was
.96%. CD4
+ T cells were stained with CFSE and co-cultured with B cells
with and without cockroach antigen. Cells were harvested at 72 hours
post-culture, and analysed via flow cytometry. (A) Representative
histogram: shaded line –T cells+CRA (250 PNU/ml), solid line – T cells+B
cells+CRA (PNU/ml) (B) Percentage of dividing cells and division index
were calculated using Flowjo
TM software. Bars represent the mean of
triplicate wells 6SEM. *=p,0.05 vs. T cells alone {=p,0.05 versus all
other groups NS=not significant. Similar results were observed in two
independent experiments.
doi:10.1371/journal.pone.0003129.g004
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Figure 6. Lung leukocyte and lymphocyte recruitment to the lungs of chronic allergen challenged mice. (A) B cell 2/2 and control mice
were chronically challenged with allergen. The numbers of CD45
+, CD4
+, CD8
+, and CD19
+ cells in the lung parenchyma were determined via flow
cytometry of enzymatic digests of whole lungs. *=p,0.05 vs. control allergic mice. (B and C) Lung eosinophilia in the lungs of chronic allergen
challenged mice. The frequency (B) and absolute number (C) of eosinophils in control and B cell 2/2 mice were determined from cytospins of
enzymatically digested lungs. Bars represent the mean of 5 mice per group 6SEM. Similar results were obtained in three independent experiments.
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Figure 5. Lung pathophysiology in control and B cell 2/2 mice. (A) Airway hyperreactivity in control and B cell 2/2 mice. AHR was assessed
by whole body plethysmography. The Y-axis corresponds to the increase in airway resistance observed following methacholine challenge. Bars
represent the mean of 8–9 mice per group 6SEM. *=p,0.05 (B) Representative histology of lung sections from control allergen challenged and B
cell2/2 mice. H&E: Hemotoxylin and eosin, PAS: periodic acid Schiff’s stain. (C) Histological scoring of PAS-stained lung sections. Bars represent the
mean of 5 mice per group 6SEM.
doi:10.1371/journal.pone.0003129.g005
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PLoS ONE | www.plosone.org 9 September 2008 | Volume 3 | Issue 9 | e3129low levels in the CNS, the ratio of B cells to T cells increases
dramatically in the later stages of multiple sclerosis [28]. A
common theme from these studies is that B cell infiltration is
associated with the most severe forms of chronic disease. The
chronicity of allergen exposure in our model may explain the
apparent the discrepancy between our results, and previously
published studies that suggested B cells do not contribute to
allergic disease [17,18].
B cells in inflamed tissues likely serve multiple functions during
chronic disease. Our studies provide in vitro and in vivo evidence
that B cell antigen presentation drives Th2 cytokine production
during allergic lung disease. B cell antigen presentation is
becoming increasingly recognized as an important contributor to
disease pathogenesis [27,33,34,35,36,37,38]. Previous studies
supporting a role for B cells in allergic disease have concluded
that the contribution of B cells is primarily via the production of
IgE [19,20]. However, specific antibodies produced by B cells in
the secondary lymphoid tissues or bone marrow could presumably
be transported via the circulation to the lungs, without requiring B
cells to be recruited directly. Furthermore, many aspects of allergic
lung disease can be generated in mast cell deficient mice,
demonstrating that IgE effector functions contribute to, but are
not sufficient for, the generation of allergic disease [39]. One
caveat to these studies is the potential role played by Fc receptor-
mediated interactions with antibodies or antibody-antigen com-
plexes. FcR signaling can be either activating or inhibiting, and
both processes play a role in regulating immune responses at
mucosal surfaces [40,41,42]. Our studies do not discount the
importance of specific antibody in the pathophysiology of allergic
lung disease, but suggest that APC function of B cells is another
important mechanism by which B cells contribute to disease. B
cells may also contribute to allergic disease via cytokine
production. Cytokine producing B cells have been described,
and reported in a number of inflammatory settings [43,44,45,46].
However, we did not observe direct Th2 cytokine production in
our studies. Previous reports from our laboratory, as well as others,
have suggested that B cells can play a regulatory role, as well
[47,48]. Still other studies have identified that B cells can indirectly
influence the T cell response by altering DC function and/or
lymph node organization, further modifying the resulting
phenotype of the response [49,50,51].
In the lungs, a number of factors may influence the relative
importance of B cells versus other APC in the development of T
cell responses: anatomical location, intrinsic antigen uptake and
processing ability, receptor specificity, and the availability of
antigen. Pulmonary B cells are located predominantly in the lung
parenchyma, though inflammation can be associated with
infiltration of the airways. Therefore, other APCs, including
dendritic cells (in the subepithelial space) and alveolar macro-
phages are more likely to initially encounter and capture antigen.
Considerable evidence points to dendritic cells as the most efficient
APC at stimulating naı ¨ve T cells [52,53,54,55,56]. However, other
studies have demonstrated that B cells in lymph nodes can present
antigen in levels that approximate dendritic cells [57]. Follow-up
studies to this suggested that cooperation between dendritic cells
and B cells takes place in the lymph nodes, with dendritic cells
‘‘handing off’’ antigen to the less mobile B cells [58]. Such a
cooperative scenario may take place in the parenchyma of allergic
lungs. Under antigen-limiting conditions, specific B cells are highly
efficient at stimulating T cell responses [59]. On the other hand,
under antigen non-limiting conditions, non-specific B cells can
serve as potent APC [56]. Thus, the inherent disadvantages of B
cells as APC (i.e. anatomic localization, poor antigen capture and
processing) may be countered by the presence of: 1) specific B cells,
which express high affinity antigen-specific receptors, and 2)
relatively high concentrations of antigen. In the context of chronic
allergic lung disease, a continuing supply of antigen, coupled with
the dramatic influx of B cells to the lungs, may serve to favor B
cells versus other antigen presenting cells.
The role of B cells in regulating IL-17 in allergic disease remains
unclear. In vitro data indicated that B cells from allergic mice
preferentially promoted T helper cell production of IL-4, IL-5,
and IL-13, but very little IFNc or IL-17 (Fig. 3). However, a
complete lack of B cells (Fig. 7) resulted in enhanced IL-17 in the
lungs. These results suggest that B cells may play a regulatory role
in limiting T cell production of IL-17, or alternatively, IL-17 in the
lungs may be produced by non-T cells. We did not detect T cell
production of IL-17 using intracellular cytokine staining of lung
lymphocytes from allergic mice, suggesting that lung IL-17 in this
system is largely non-T cell-derived. In contrast, mice that received
MHC II2/2 B cells had decreased IL-17, relative to mice
receiving WT B cells, suggesting that WT B cells were promoting
IL-17 production. Thus apparent paradox may arise from
compensatory mechanisms in knockout mice and/or changes to
the lungs following irradiation. Although Th2 cytokines (IL-13, in
particular) play a role in promoting mucus hyper secretion, high
IL-17 production is also associated with mucus hyper section
[23,24,25]. The increased IL-17 in B cell2/2 mice may promote
mucus hyper secretion in these mice, despite lower levels of Th2
cytokines (Fig. 7).
In conclusion, our studies are the first to show that B cells
contribute to chronic allergic lung disease via promoting Th2
responses, and strongly suggest that B cell antigen presentation
contributes to the pathogenesis of this disease.
Materials and Methods
Mice
Female mMT, I-A
b 2/2, C57Bl/6, DO11.10, and Balb/C
mice were obtained from the Jackson Laboratories. B cell deficient
mMT mice are on the C57Bl/6 background. All other experiments
were performed using mice on a Balb/c background. Mice were
housed under pathogen-free conditions in enclosed filter-topped
cages. Clean food and water were given ad libitum. The mice were
handled and maintained using micro isolator techniques, with
daily veterinarian monitoring. Bedding from the mice was
transferred weekly to cages of uninfected sentinel mice that were
subsequently bled at weekly intervals and found to be negative for
antibodies to mouse hepatitis virus, Sendai virus, and Mycoplasma
pulmonis. All studies involving mice were approved by the
University Committee on Use and Care of Animals (UCUCA)
at the University of Michigan.
Figure 7. Th1/Th2 associated cytokines in the lungs of allergen challenged mice. B cell 2/2 and control mice were chronically challenged
with allergen, and cytokine levels were assesed in bronchoalveolar lavage (B) and lung homogenates (A) via Bioplex multiplex assay. Bars represent
the mean of 6 mice per group 6SEM, except naive, for which n=2. (C) Intracellular cytokine staining of CD4 T cells from the lungs of control and B
cell2/2 allergen challenged mice. Bars represent the mean of 6 mice per group 6SEM. *=p,0.05 versus control allergen challenged. Similar results
were obtained in two independent experiments.
doi:10.1371/journal.pone.0003129.g007
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Figure 8. Role of B cell expression of MHC II in allergic disease. (A) Lung cytokines and (B) mucus-associated gene expression in the lungs of
mMT/I-A
b2/2 mice and mMT/WT mice. Mice with MHC II deficient (mMT/I-A
b2/2 mice) or normal (mMT/WT ) B cells were generated using mixed
bone marrow chimeras, and chronically challenged with allergen. The levels of cytokines in the lungs were determined from lung homogenate
samples via Bioplex multiplex assay. The expression of mucus associated genes was assessed by real-time PCR using whole lung RNA. Bars represent
the mean 6SEM of 4 mice per group. *=p,0.05 Similar results were obtained in two independent experiments.
doi:10.1371/journal.pone.0003129.g008
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The cockroach antigen sensitization protocol is outlined in
Figure 1A. Female mice (4- to 6-week-old) were immunized on day
0 intraperitoneally and subcutaneously with 1000 Protein
Nitrogen Units (PNU) cockroach allergen extract (CRA, Hollis-
ter-Stier) emulsified in incomplete Freund’s adjuvant (Sigma). This
cockroach allergen is a skin test/immunotherapy grade prepara-
tion that has very little endotoxin contamination (,20 ng/ml)
[60]. Beginning at day 14, mice received intranasal challenges of
150 PNU CRA every four days (days 14, 18, 22, 26, 30) followed
by intratracheal challenges of 400 PNU on day 34 and 36.
Measurement of airway hyperreactivity
Airway hyperreactivity (AHR) was assessed as previously
described [60,61,62,63,64,65]. AHR was measured using a Buxco
mouse plethysmograph which is specifically designed for the low
tidal volumes (Buxco). The mouse to be tested was anesthetized
with sodium pentobarbital and intubated via cannulation of the
trachea with an 18-gauge metal tube. The mouse was subsequently
ventilated with a Harvard pump ventilator (tidal volume=0.4 ml,
frequency=120 breaths/min, positive end-expiratory pressure
2.5–3.0 cm H2O) and the tail vein was cannulated with a 27 gauge
needle for injection of the methacholine challenge. The plethys-
mograph was sealed and readings monitored by computer. As the
box is a closed system, a change in lung volume will be represented
by a change in box pressure (Pbox) that was measured by a
differential transducer. Once baseline levels had stabilized and
initial readings were taken, a methacholine challenge was given via
the cannulated tail vein. After determining a dose–response curve
(0.001–0.5 mg), an optimal dose was chosen, 0.250 mg of
methacholine. This dose was used throughout the rest of the
experiments in this study. After the methacholine challenge, the
response was monitored and the peak airway resistance was
recorded as a measure of airway hyperreactivity.
Lung, lymph node, spleen, and bone-marrow leukocyte
isolation
Lung leukocytes were isolated via collagenase dispersion. Right
lungs from each mouse were excised, washed in PBS, minced and
digested enzymatically for 40 minutes in 15 ml/lung of digestion
buffer (RPMI, 5% FCS, antibiotics, 1 mg/ml collagenase (Roche
Applied Science), and 30 mg/ml DNase (Sigma)). Following
erythrocyte lysis using ammonium chloride (NH4Cl) buffer, cells
were washed, and resuspended in media (RPMI, 5% FCS,
antibiotics). Total lung leukocyte numbers were assessed in the
presence of 0.04% trypan blue using a hemocytometer; viability
was .90%. Eosinophil frequency was determined by Wright-
Giemsa staining of samples cytospun onto slides. Lung-associated
lymph nodes (LALN) and spleens were excised and cells dispersed
with the plunger of a 3 ml syringe. Bone marrow cells were
isolated via flushing femurs and tibias with PBS +1% FCS.
Erythrocytes were lysed using NH4Cl buffer, and cells were
resuspended in media. For preparation of lung lymphocytes for
fluorescence-based sorting (FACS), lung leukocytes were enriched
by centrifugation over a 40% isotonic PercollH (Sigma) gradient
for 30 min at 20006g. The cell pellet was resuspended in media
and plated in 100 mm cell culture dishes. Non-adherent cells were
harvested and stained for FACS.
B cell ELISPOT
High-protein binding filtration plates (Millipore) were coated
with 400 PNU/ml CRA in PBS. Plates were blocked for 1 hour
with 2% FCS in PBS. After washing, single cell suspensions from
each organ were added at varying concentrations (5610
5–2610
6)
in media, and incubated overnight at 37u 5% CO2. After washing
away cells, spots corresponding to B cells secreting antibody were
visualized using HRP conjugated anti-mouse Ig and AEC
substrate, and counted using a stereo dissection microscope.
Single cell suspensions from each organ varied in the frequency of
B cells (,50% in LALN, ,10% in Lungs), so the frequency of
spots per well was normalized to B cell number using flow
cytometry by the following calculation:
# spots

105 cells
 
B cell frequency determined by flow cytometry ðÞ Þ
| 10 ðÞ ~CRA
specific B cells per 106 B cells:
Flow cytometry
For surface staining alone, leukocytes were washed and
resuspended at a concentration of 10
7 cells/ml in Flow Buffer
((PBS+1% FCS+0.1% NaN3 (Sigma)), Fc receptors were blocked
by the addition of anti-CD16/32 (Fc block
TM, BD Biosciences).
Leukocytes were stained with the following monoclonal antibodies,
per manufacturer’s instructions: anti-CD45 (30-F11), CD19 (1D3),
CD4 (RM4-5), CD8 (53-6.7), CD40 (3/23), anti-I-A
d (AMS-32.1),
(all from BD Biosciences), CD11c (N418), CD80 (16-10A1), CD86
(G4, all from eBiosciences). A minimum of 50,000 events were
acquired on a dual-laser Cytomics FC500
TM flow cytometer
(Beckman Coulter) using Flowjo
TM software (Treestar). The
absolute number of each cell type was determined by multiplying
the percentage6total cell number isolated from each organ. For
fluorescence activated cell sorting (FACS), cells were stained as
above, except that azide free flow buffer was used. Cells were
sorted on a BD FACSAria (BD Biosciences) at the University of
Michigan Flow Cytometry Core. Cells were pre-gated on CD45 to
exclude epithelial cell debris, negatively gated for CD11c, and
positively gated for either CD4 or CD19. Resulting cell
populations were greater than 99% pure and ,0.05% CD11c
+,
and greater than 95% viable as determined by trypan blue
exclusion.
Lung T cell/B cell co cultures
Lung lymphocytes were isolated from the lungs via enzymatic
digestion and enriched via density gradient centrifugation as
described above. The resulting cell suspension was subjected to
Table 2. T cell and dendritic cell numbers in the lungs of
mMT/I-A
b2/2 mice and mMT/WT mice.
Cell Type mMT/WT mMT/ I-A
b2/2
CD4
+ 7.1060.72 6.0460.06
CD8
+ 3.3260.41 2.5360.35
CD11b
hiCD11c
hi 5.9960.48 4.6760.28
Mice with MHC II deficient (mMT/I-A
b2/2 mice) or normal (mMT/WT ) B cells
were generated using mixed bone marrow chimeras, and chronically
challenged with allergen. The percentage of each cell type was determined by
flow cytometric analysis of enzymatically digested lungs, and used to calculate
absolute cell numbers.
doi:10.1371/journal.pone.0003129.t002
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+ T cells and B
cells were co-cultured in complete media (RPMI, 5% FCS,
antibiotics, non-essential amino acids, L-glutamine (all obtained
from Mediatech, Inc.),50 mM 2-mercaptoethanol (Sigma)) at a
predetermined optimal ratio of 4:1 (200, 000 T:50,000 B) in 96
well plates, either with or without cockroach antigen, and the
levels of IL-4, IL-5, IL-13, IFNc, and IL-17 were measured in
supernatants harvested after 72 hrs.
Intracellular flow cytometry
Leukocytes were cultured for 6 hours at 5610
6 cells/ml in 48-
well plates in the presence of 2 mg/ml plate bound anti-CD3 (145-
2C11, BD Biosciences) and Brefeldin A (in the form of Golgi-
plug
TM, BD Biosciences). Non-adherent cells were harvested and
staining for cell-surface molecules was done as described above.
Cells were washed of excess surface stains, fixed and permeabilized
using Cytofix/Cytoperm
TM (BD Biosciences), and stained using
anti-IL4 (11B11, BD Biosciences) in permeabilization buffer (FA
Buffer+0.1% saponin (Sigma)) at 4uC for 30 mins. The specificity
of anti-cytokine antibodies was tested by comparing staining of
experimental samples to a minimum of two of three negative
controls: 1) isotype control 2) excess unlabelled antibody and/or 3)
pre-incubation of antibody with recombinant cytokine.
Quantitative PCR (qPCR)
RNA was isolated from the lower left lobes of lungs by
homogenization using Trizol (Invitrogen). Levels of Gob5 and
Muc5ac mRNA were assessed using quantitative PCR (qPCR)
analysis (TaqMan) as previously described [66]. Quantification of
the genes of interests were normalized to GAPDH and expressed
as fold increases over naive or unstimulated controls.
Cytokine quantification
Protein levels in the lungs were determined from homogenized
upper left lobes. Protein levels of IL-4, IL-5, IL13, IL-17, and
IFNc were quantitated using commercially available X-Plex bead-
based cytokine assay purchased from Bio-Rad Laboratories, and
analyzed using the Bio-Plex system.
Proliferation
In vitro proliferation was assayed using an in vitro fluorescence-
based assay. MACS purified CD4
+ T cells were stained with 5 mM
5-(and 6-) carboxyfluorescein diacetate, succinimidyl ester (CFSE,
Molecular Probes) in PBS 5% FCS for 7 minutes at room
temperature. Cells were washed several times to remove excess
CFSE and a total of 5610
5 T cells were co-cultured with 1610
5 B
cells MACS- purified B cells and CRA. A minimum of 50,000
events were acquired on a dual-laser Cytomics FC500
TM flow
cytometer (Beckman Coulter) and analyzed using Flowjo
TM
software (Treestar). The software was used to calculate percent
divided, as well as division index. Division Index is the average
number of cell divisions that the responding cells underwent.
Histology
Right lobes of the lungs were isolated and immediately fixed in
10% neutral buffered formalin. Lung samples were subsequently
processed, embedded in paraffin, sectioned, and placed on L-
lysine-coated slides, and stained using standard histological
techniques using Hemotoxylin and Eosin (H&E) and Periodic-
acid Schiff (PAS). PAS staining was done to identify mucus and
mucus-producing cells. Slides were scored for the intensity of PAS
staining by N.W.L. blinded to the identity of the samples.
Mixed bone-marrow chimeras
MHC II deficient B cell mice and pseudo-wild type mice were
generated as previously described [27]. Briefly, B cell deficient
mMT mice were lethally irradiated (1200 rads) and reconstituted
with 10
7 bone marrow cells within four hours. Mice were
reconstituted with either 75% mMT bone marrow+25% wild-type
bone marrow or 75% WT+25% I-Ab 2/2 bone marrow. Mice
were rested for eight weeks before chronic allergen challenge.
Statistical analysis
All values are means6standard error of the mean (SEM), unless
otherwise indicated. Differences between two means were
evaluated using the Student t test, (assuming unequal variance
where dictated by F test) with p,0.05 considered to be statistically
significant. Differences between greater than two groups were
assessed via ANOVA with Tukey-Kramer post-test comparison.
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